GlobeImmune Initiates Phase 1 Clinical Trial With NCI In CEA - Metatastic Cancers
GlobeImmune, Inc. announced the initiation of a Phase 1 clinical trial to investigate the safety and tolerability of a new Tarmogen, GI-6207, in patients with metastatic cancers that over-express carcinoembryonic antigen (CEA). This is the third new Tarmogen(R) product candidate to enter human clinical trials over the last four years. James L. Gulley, M.D., Ph.D., F.A.C.P.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment